Precipio (NASDAQ: PRPO) is one of 188 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Precipio to related businesses based on the strength of its profitability, valuation, institutional ownership, earnings, dividends, risk and analyst recommendations.
Earnings & Valuation
This table compares Precipio and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Precipio||$1.55 million||-$7.61 million||N/A|
|Precipio Competitors||$217.40 million||-$39.40 million||-65.34|
This table compares Precipio and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations and price targets for Precipio and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Biotechnology & Medical Research” companies have a potential upside of 13.77%. Given Precipio’s peers higher possible upside, analysts plainly believe Precipio has less favorable growth aspects than its peers.
Institutional and Insider Ownership
14.4% of Precipio shares are held by institutional investors. Comparatively, 47.4% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 24.7% of Precipio shares are held by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Precipio has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, Precipio’s peers have a beta of 1.52, meaning that their average stock price is 52% more volatile than the S&P 500.
Precipio peers beat Precipio on 6 of the 9 factors compared.
Precipio, Inc., formerly Transgenomic, Inc., is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market, enabling the use of blood and other bodily fluids for diagnosis, monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms, including Sanger, Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha, Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted.
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.